Company Filing History:
Years Active: 2014-2020
Title: Hiroaki Wakimoto: Innovator in Oncolytic Virus Therapy
Introduction
Hiroaki Wakimoto is a prominent inventor based in Newton, MA, known for his groundbreaking work in the field of oncolytic virus therapy. With a total of three patents to his name, he has made significant contributions to cancer treatment methodologies.
Latest Patents
Wakimoto's latest patents focus on a recombinant oncolytic virus that comprises a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV, which is designed to target resistant tumors. The patent details various forms of oHSV and secreted TRAIL, along with host cells and therapeutic formulations that utilize the recombinant oncolytic virus. Additionally, it outlines methods for treating cancer in subjects by administering therapeutic formulations containing this innovative virus.
Career Highlights
Hiroaki Wakimoto is affiliated with The General Hospital Corporation, where he continues to advance research in cancer therapies. His work has been instrumental in developing new treatment options for patients with resistant tumors.
Collaborations
Wakimoto collaborates with notable colleagues, including Khalid Shah and Kaoru Tamura, who contribute to his research efforts and innovations in the field.
Conclusion
Hiroaki Wakimoto's contributions to oncolytic virus therapy represent a significant advancement in cancer treatment. His innovative approach and collaborative efforts continue to pave the way for new therapeutic options in oncology.